Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E30.11 EPS (ttm)2.77 Insider Own9.30% Shs Outstand2.61B Perf Week-0.30%
Market Cap217.50B Forward P/E16.29 EPS next Y5.11 Insider Trans0.39% Shs Float2.53B Perf Month2.56%
Income6.67B PEG4.88 EPS next Q1.19 Inst Own10.20% Short Float0.17% Perf Quarter9.60%
Sales49.78B P/S4.37 EPS this Y-33.30% Inst Trans0.11% Short Ratio2.41 Perf Half Y10.95%
Book/sh30.43 P/B2.74 EPS next Y7.40% ROA5.10% Target Price93.25 Perf Year-16.16%
Cash/sh- P/C- EPS next 5Y6.17% ROE9.10% 52W Range68.87 - 100.82 Perf YTD0.54%
Dividend2.72 P/FCF109.68 EPS past 5Y-7.50% ROI7.80% 52W High-17.42% Beta0.58
Dividend %3.27% Quick Ratio0.60 Sales past 5Y-0.50% Gross Margin65.00% 52W Low20.90% ATR1.04
Employees118000 Current Ratio0.90 Sales Q/Q-1.70% Oper. Margin16.90% RSI (14)58.12 Volatility1.03% 0.88%
OptionableYes Debt/Eq0.36 EPS Q/Q-0.80% Profit Margin13.60% Rel Volume0.88 Prev Close82.08
ShortableYes LT Debt/Eq0.22 EarningsJul 19 BMO Payout94.00% Avg Volume1.80M Price83.26
Recom2.40 SMA201.12% SMA503.73% SMA2005.56% Volume1,576,730 Change1.44%
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Jul-29-16 01:57PM  Amgens Bone Health Drug Saw Strong Revenue Growth in 2Q16
01:57PM  Growth Products Drove Amgens Revenue Performance in 2Q16
01:44PM  ETFs with exposure to Novartis AG : July 29, 2016
01:40PM  Amgen Continued to Manage Life Cycles of Its Mature Brands in Q2
Jul-28-16 02:13PM  AstraZeneca (AZN) Stock Up After Q2 Earnings, Revenue Beat
08:34AM  AstraZeneca a bid target again? CEO says someone may spot value
05:43AM  AstraZeneca a takeover target again? CEO not commenting
Jul-27-16 11:04AM  Analyst Recommendations for Roche: Buy, Hold, or Sell?
09:09AM  BIIB Continues to Lead the MS Treatment Market in the US in 2016
Jul-26-16 10:15AM  Novartis AG :NVS-US: Earnings Analysis: Q2, 2016 By the Numbers : July 26, 2016
09:04AM  Newly Acquired Products Boost GlaxoSmithKlines Earnings
09:04AM  What Do the Recent Changes in Novartiss 2Q16 Valuation Tell Us?
08:21AM  An Investing Overview of the Multiple Sclerosis Market at Motley Fool
Jul-25-16 11:04AM  How Do the Majority of Analysts Rate Novartis after 2Q16?
09:07AM  Sales Performance Analysis of Roches Pharmaceuticals Division
09:07AM  GSK 2Q16 Earnings: Did Pharmaceuticals Grow?
08:49AM  Glaxo (GSK) Q2 Earnings: Can the Stock Pull a Surprise?
Jul-22-16 04:11PM  Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other
03:39PM  GlaxoSmithKline Segments That Drive Companys Rising Revenues
01:15PM  What Role Did Innovative Medicines Play in Novartiss 2Q16 Earnings?
01:07PM  What Are Lillys 2Q16 Estimates and Expectations for Elanco?
Jul-21-16 02:01PM  Research Reports on Facebook (FB), Tesla (TSLA) & Others Zacks
01:49PM  Inside the Foreign Exchange Impact on Novartiss Growth in 2Q16
01:49PM  How Did Novartiss 2Q16 Earnings Stand up to Analyst Estimates?
08:40AM  Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science
02:20AM  Roche Beats First-Half Forecasts as Cancer Drug Sales Rise
Jul-20-16 10:15AM  Novartis (NVS) Tops Q2 Earnings & Sales, Expenses to Grow
09:44AM  These new drugs might never get a chance to save the U.S. $250 billion at MarketWatch
Jul-19-16 07:00PM  Pricing dispute hits supply of TB drugs in Pakistan Reuters
05:30PM  Amgen Finally Scores a Win in Its Big Copycat Drug Battle With Novartis at Fortune
04:47PM  Novartis Shares Slip Tuesday on Falling Profit at TheStreet
04:35PM  What Lilly Expects for Revenue Growth in 2Q16
01:41PM  Novartis Set To Become Biosimilar Pioneer By 2020
01:07PM  Novartis Set To Become Biosimilar Pioneer By 2020 at Forbes
12:55PM  ETFs with exposure to Novartis AG : July 19, 2016
10:06AM  Medical Stocks to Post Earnings This Week: ABT, BIIB, ALIOF
09:59AM  Novartis profit slips as generic drug competition hits sales
09:11AM  [$$] Novartis braced for US price shake-up after presidential election at Financial Times
08:55AM  Novartis (NVS) Stock Down on Profit Warning
08:42AM  U.S. FDA knocks back Novartis copy of Amgen's drug Neulasta Reuters
07:58AM  Early movers: GS, UNH, JNJ, NFLX, PM, CMG, IBM, YHOO, AMZN & more at CNBC
06:05AM  Novartis beats 2Q profit forecasts
05:35AM  Novartis Ramps Up Heart Drug Spending as Top Seller Goes Generic at Bloomberg
04:07AM  [$$] Novartis Warns on Profit at The Wall Street Journal
03:43AM  Novartis, world's top drugmaker, plays down Brexit threat Reuters
03:16AM  Novartis warns 2016 profit may fall on higher heart drug spending
02:22AM  Novartis Second-Quarter Earnings, Revenue Fall Less Than Forecast
02:07AM  Novartis (NVS) Beats Earnings & Sales in Q2
01:05AM  Novartis Says Profit May Drop on Entresto Spending, Gleevec at Bloomberg
Jul-18-16 11:07AM  How Much Potential Does Promacta Hold?
10:12AM  Why Earnings Season Could Be Great for Novartis AG (NVS)
09:45AM  Why Novartiss 2Q16 Revenues Are Expected to Fall
09:45AM  Novartiss 2Q16 Earnings: Whats Expected?
09:08AM  Ligand Pharmaceuticalss Portfolio Pyramid as Its Valuation Catalyst
08:02AM  3 Drug Stocks to Report Earnings on Jul 19: JNJ, NVS, NEOG
Jul-17-16 05:06PM  3 Big-Cap Drugmakers Reporting Earnings This Week
01:59PM  Forget the Me-Too Cancer Drugs -- These Breakthroughs Are Where You Want to Invest at Motley Fool
Jul-15-16 08:02PM  How Much Upward Potential Does Roche Really Have?
12:10PM  Novartis (NVS) Likely to Beat Q2 Earnings: Stock to Gain?
11:07AM  What Is Ligand Pharmaceuticalss Expected Revenue Growth in 2016?
Jul-14-16 04:22PM  3 Big Pharma Stocks That Could Raise Their Dividends at Motley Fool
12:06PM  Novartis' Enbrel Biosimilar Gets FDA Panel Recommendation
11:45AM  FDA committee supports approval of Sandoz biosimilar for Amgen's blockbuster Enbrel at MarketWatch
10:06AM  How Can Celators Portfolio Complement Jazz Pharmaceuticals?
08:56AM  Coverage Initiated on Select Healthcare Stocks
Jul-13-16 03:03PM  U.S. FDA panel supports Novartis version of Amgen arthritis drug Reuters
02:04PM  GE Dives Deeper Into Cell Therapy As Juno, Kite Take Off
12:07PM  Teva Forecasts Growth After Expected Actavis Deal Closes
Jul-12-16 05:49PM  FDA Panel Resoundingly Backs Amgen's Biosimilar Humira
05:06PM  The CHMP Just Recommended the Extension of These Drugs Therapeutic Indications
04:59PM  Amgen Moves Closer to Selling Competitor for AbbVies Humira at Bloomberg
Jul-11-16 01:50PM  Top 7 Research Reports for July 11, 2016
11:37AM  UPDATE 2-Novartis copy of Amgen arthritis drug highly similar -FDA staff Reuters
09:23AM  Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
08:13AM  Novartis copy of Amgen arthritis drug highly similar -FDA staff Reuters
Jul-10-16 07:21AM  Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors at Motley Fool
Jul-08-16 04:19PM  Amgen's Biosimilar Humira Gets FDA Support Ahead Of Panel
06:50AM  Feuerstein: Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks
Jul-05-16 11:05AM  AbbVies Tests of Imbruvica with Venclexta for Oncology Therapy
Jul-04-16 09:07AM  Pfizers Products with Declining Revenues: What Does That Mean?
Jul-03-16 11:40AM  These 5 Big Stocks Are Breaking Out This Summer
Jul-02-16 12:01AM  [$$] Biotech Bargain at Barrons.com
Jul-01-16 04:43PM  Novartis' Systemic Mastocytosis Drug Positive in Phase II
11:07AM  What Are the Benefits of the Novartis-Xencor Alliance to Xencor?
09:09AM  How Could the Novartis-Xencor Alliance Benefit Novartis?
06:00AM  'Mad Money' Lightning Round: You Should Be Buying Visa
Jun-30-16 07:00PM  Cramer: This stock's overreaction could trigger a comeback at CNBC
03:54PM  How Did Investors Respond to the Novartis-Xencor Alliance?
03:54PM  What Is Xencors XmAb Technology?
03:54PM  The Novartis-Xencor Collaboration Agreement: The Details
12:25PM  ETFs with exposure to Novartis AG : June 30, 2016
11:01AM  [$$] Who Will Acquire Medivation? at Barrons.com
Jun-29-16 06:20PM  Xencor Stock Up On Cancer Drugs Partnership with Novartis
09:08AM  Inside the CHMPs Refusal of Novartiss Arzerra as a Maintenance Treatment
07:00AM  5 Wide-Moat Stocks Now Selling at a Discount at Morningstar
Jun-28-16 06:23PM  Xencor signs cancer-drug deal with Novartis; its stock surges 32% at Los Angeles Times
04:31PM  Novartis, Xencor Ink $2.4 Billion Licensing Deal In Blood Cancer
03:43PM  Why Xencor Inc's Shares Are Skyrocketing Today at Motley Fool
03:32PM  Novartis AG :NVS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016
11:06AM  Mylans Key Developments and Big Plans: What You Should Know
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Institutes for BioMed10% OwnerMay 11Buy18.00277,7774,999,9865,573,658May 11 06:57 PM
Novartis Bioventures Ltd10% OwnerApr 12Buy10.00300,0003,000,0002,310,924Apr 12 05:09 PM
Novartis Bioventures Ltd10% OwnerFeb 17Buy8.00375,0003,000,0001,873,791Feb 17 06:47 PM